



Press release

Paris, July [9], 2013

Kurma Life Sciences Partners and Cydan Enter Collaboration to Further Expand Global Network and Strengthen Ability to Identify New Rare Disease Assets

Kurma Life Sciences Partners today announced collaboration with Cydan Development, Inc., an orphan drug accelerator that identifies strategic de-risking investments for development programs around rare genetic diseases. The collaboration leverages global networks and the ability of both organizations to work with key opinion leaders, eminent research institutes and patient foundations on both sides of the Atlantic.

“The collaboration with Cydan will strengthen our U.S. network, as well as help to harmonize our strategy with the international reality of orphan drug discovery. We look forward to working closely with the Cydan team”, said Thierry Laugel and Rémi Droller, Managing Partners of Kurma Life Sciences Partners.

Cristina Csimma, Pharm.D., chief executive officer of Cydan, added:

“The flexibility of Cydan’s model enables us to collaborate with multiple organizations, leverage our development expertise with Kurma’s entrepreneurial approach and harness both groups’ relationships with top European academic institutions. The collaboration will build upon our global network and strongly positions us to identify programs with therapeutic and commercial potential.”

Additional terms of the agreement are not being disclosed.



About Cydan - www.cydanco.com

Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator's model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. Cydan was launched in 2013 by a management team with extensive drug development and commercialization experience and with financing from leading investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities. The accelerator is based in Cambridge, Mass.

About KLS Partners - www.kls-partners.com

Founded in July 2009, KLS Partners is a key European player in venture capital, development capital and technology transfer in the field of life sciences (biotechnologies, health, nutrition, environmental sciences), notably through the Kurma Biofund venture capital fund and strategic partnerships with forefront European biotechnology medical research centres.

Media contact

NewCap. - Nicolas Merigeau : +33(0)1 44 51 94 98 - nmerigeau@newcap.fr